US Pre-Market SEC Filings Roundup — February 16, 2026

17-02-2026

LOUISIANA-PACIFIC CORP filed a Form 8-K on 2026-02-17 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for the change, timing, or any financial metrics are disclosed. This appears to be a routine leadership disclosure with no quantified positive or negative impacts provided.

17-02-2026

Republic Services, Inc. filed a Form 8-K on February 17, 2026 (AccNo: 0001060391-26-000072, size: 11 MB), reporting under Item 5.03 regarding amendments to Articles of Incorporation or Bylaws, or a change in fiscal year. No specific details on the nature, scope, or implications of the amendments or changes are disclosed in the filing summary. No financial metrics, transaction values, or other quantitative data are mentioned.

17-02-2026

MGP Ingredients Inc filed an 8-K on February 17, 2026 (AccNo: 0000835011-26-000006), disclosing Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Specific details including names, titles, reasons for changes, or any quantitative impacts are NOT_DISCLOSED. No positive or negative metrics, financial data, or further context provided.

17-02-2026

CAPITAL ONE FINANCIAL CORP filed an 8-K on February 17, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details, financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. This is a multi-item voluntary filing with no mentioned positive or negative performance indicators.

17-02-2026

17-02-2026

Greenpro Capital Corp. filed an 8-K on February 17, 2026, under Item 1.01 disclosing entry into a material definitive agreement. Item 9.01 includes financial statements and exhibits. No specific details on the agreement terms, transaction value, financial impacts, or other metrics are disclosed.

17-02-2026

Allegion plc filed an 8-K on February 17, 2026 (AccNo: 0001579241-26-000006), reporting Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, or other financial metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with no detailed quantitative data available.

17-02-2026

Honeywell International Inc filed a Form 8-K on February 17, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing involves a voluntary disclosure to comply with Regulation FD, with exhibits attached, but no specific financial metrics, transactions, or performance data are detailed. No positive or negative metrics are disclosed, providing only structural filing information.

17-02-2026

MODINE MANUFACTURING CO filed an 8-K on February 17, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transactions, period-over-period comparisons, or other quantitative data are disclosed in the provided filing information. The filing size is 5 MB, but contents of the disclosure and exhibits are NOT_DISCLOSED.

• ·AccNo: 0001104659-26-015568
• ·Filing size: 5 MB

17-02-2026

DAILY JOURNAL CORP filed an 8-K on February 17, 2026 (AccNo: 0001437749-26-004210), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet changes, period-over-period comparisons, or other quantitative financial metrics were disclosed in the provided filing information. This is a standard voluntary disclosure of financial results with attached exhibits.

17-02-2026

The company filed an 8-K on February 17, 2026 (AccNo: 0001104659-26-015557), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item, general filing of 2 MB size with no specific details on the nature of other events, transaction values, financial metrics, or exhibits provided. No quantitative data, named entities, or directional impacts are disclosed.

17-02-2026

Portland General Electric Co /OR/ filed a Form 8-K on 2026-02-17 reporting multiple material items: entry into a material definitive agreement (Item 1.01), results of operations and financial condition (Item 2.02), creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). This is a multi-item filing likely combining earnings release with new agreement and financing details. Specific transaction values, financial metrics, period-over-period changes, guidance, or impacts are NOT_DISCLOSED.

17-02-2026

EKSO Bionics Holdings, Inc. filed a multi-item Form 8-K on February 17, 2026, disclosing events under Items 1.01 (Entry into a Material Definitive Agreement), 2.02 (Results of Operations and Financial Condition), 3.02 (Unregistered Sales of Equity Securities), 3.03 (Material Modifications to Rights of Security Holders), 5.01 (Changes in Control of Registrant), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), 5.03 (Amendments to Articles of Incorporation or Bylaws), and 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative impacts are disclosed. The combination of control changes, equity sales, and governance modifications suggests potential strategic shifts, dilution risks, and operational updates without further details provided.

17-02-2026

National Energy Services Reunited Corp. filed an 8-K on February 17, 2026 (AccNo: 0001493152-26-006872), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but no specific revenue, earnings, margins, or other metrics are provided in the filing summary. No positive or negative performance indicators, guidance, or comparisons are detailed.

17-02-2026

Ralliant Corp filed an 8-K on February 17, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details on the disclosure content, financial metrics, transactions, or events are provided in the filing summary. The filing size is 4 MB, indicating potential attachments such as exhibits.

17-02-2026

Cineverse Corp. disclosed entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01), representing a key strategic transaction; however, it also created a direct financial obligation (Item 2.03) and involved unregistered sales of equity securities (Item 3.02), potentially introducing leverage and dilution risks. Regulation FD disclosure was provided (Item 7.01) with financial statements and exhibits (Item 9.01). No specific deal terms, parties, values, or financial metrics are disclosed.

17-02-2026

Armada Hoffler Properties, Inc. filed an 8-K on February 17, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results, but specific metrics such as revenue, earnings, or guidance are NOT_DISCLOSED. No period-over-period comparisons, positive or negative changes, or other quantitative details are provided in the filing information.

17-02-2026

Leidos Holdings, Inc. filed an 8-K on February 17, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, guidance, or quantitative data are disclosed in the provided filing information. This is a standard multi-item earnings-related disclosure with no directional performance indicators available.

17-02-2026

Hyatt Hotels Corp filed an 8-K on 2026-02-17 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, names of individuals involved, appointment or resignation status, reasons for the change, and any compensatory arrangements are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events were mentioned in the provided filing information.

17-02-2026

JFB Construction Holdings filed an 8-K on February 17, 2026 (AccNo: 0001493152-26-006871), disclosing an event under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on affected positions, individuals involved, reasons for change, or any financial metrics are disclosed. Sector information is not specified.

• ·Filing date: 2026-02-17
• ·Accession Number: 0001493152-26-006871
• ·File size: 208 KB
• ·Event type: Officer Change

17-02-2026

Sonoco Products Co filed an 8-K on February 17, 2026, under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, guidance, or other quantitative metrics are detailed in the provided filing information. This represents a standard earnings-related disclosure without extracted numerical data.

17-02-2026

nVent Electric plc filed an 8-K on February 17, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 discloses financial statements and exhibits. No specific details on the agreement, transaction size, parties, financial impacts, or quantitative metrics are provided.

17-02-2026

Datavault AI Inc. filed a Form 8-K on February 17, 2026, disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This multi-item filing announces financial results with attached exhibits. No specific revenue, earnings, comparisons, guidance, or other quantitative metrics are disclosed.

17-02-2026

IDEAYA Biosciences, Inc. filed an 8-K on February 17, 2026 (AccNo: 0001193125-26-052741, Size: 344 KB), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or quantitative financial metrics are mentioned in the filing description. This is a standard financial results announcement with no disclosed positive or negative performance indicators.

17-02-2026

Matthews International Corp filed an 8-K on February 17, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 provides financial statements and exhibits. No specific transaction details, dollar values, strategic impacts, or financial metrics are disclosed.

17-02-2026

CEA Industries Inc. filed a Form 8-K on February 17, 2026 (AccNo: 0001493152-26-006862, Size: 280 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the financial statements and exhibits are disclosed. No quantitative metrics, financial impacts, or strategic information are provided.

17-02-2026

SPACSphere Acquisition Corp. filed an 8-K on 2026-02-17 under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits) related to a merger/acquisition event. No specific details on deal structure, parties involved, valuation, financial terms, or strategic rationale were explicitly stated. Sector not specified, limiting assessment of market implications.

• ·Accession Number: 0001829126-26-001360
• ·File Size: 467 KB

17-02-2026

BioRestorative Therapies, Inc. filed an 8-K on 2026-02-17 reporting under Item 1.01 entry into a material definitive agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the agreement, transaction terms, financial impacts, or quantitative metrics disclosed in the provided information. No positive or negative performance metrics, period-over-period changes, or guidance revisions are mentioned.

17-02-2026

Proem Acquisition Corp. I filed an 8-K on 2026-02-17 disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger or acquisition. The filing also covers unregistered sales of equity securities (Item 3.02), departures/elections of directors/officers and compensatory arrangements (Item 5.02), amendments to articles of incorporation or bylaws (Item 5.03), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No specific deal parties, structure, valuation, financial metrics, or impacts are disclosed.

17-02-2026

TG-17, Inc. filed a Form 8-K on February 17, 2026, under Item 1.01 disclosing entry into a material definitive agreement and Item 9.01 providing financial statements and exhibits. No details on the agreement's nature, counterparties, terms, value, or financial impacts are disclosed. This is a multi-item mandatory filing with no quantitative metrics or period-over-period comparisons provided.

17-02-2026

Applied Digital Corp. filed an 8-K on February 17, 2026, reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No quantitative details, financial impacts, positive or negative metrics, or period-over-period comparisons are provided in the available information.

17-02-2026

Accuray Inc filed a Form 8-K on February 17, 2026 (AccNo: 0001437749-26-004223, Size: 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the Regulation FD disclosure, financial statements, exhibits, transactions, metrics, or events are provided in the filing summary. Critical financial or operational data is NOT_DISCLOSED.

17-02-2026

Bioxytran, Inc. filed an 8-K on 2026-02-17 disclosing Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, events, financial impacts, or quantitative metrics were provided in the filing summary. No positive or negative metrics were mentioned.

17-02-2026

Artificial Intelligence Technology Solutions Inc. filed an 8-K on February 17, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or the content of any exhibits are provided. No quantitative metrics, positive or negative changes, or financial impacts are mentioned.

17-02-2026

17-02-2026

SOMNIGROUP INTERNATIONAL INC. filed an 8-K on February 17, 2026, under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, transaction values, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item filing focused on financial updates and exhibits.

17-02-2026

InfuSystem Holdings, Inc. filed a Form 8-K on February 17, 2026, under Item 7.01 Regulation FD Disclosure. This voluntary filing discloses material non-public information to comply with Regulation FD requirements. No specific financial metrics, transactions, events, or quantitative data are detailed in the provided filing information.

17-02-2026

CNH Industrial N.V. filed an 8-K on 2026-02-17 reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 8.01 (Other Events), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing details. This is a multi-item voluntary disclosure typical for earnings releases.

17-02-2026

AG Mortgage Investment Trust, Inc. filed a Form 8-K on February 17, 2026, reporting solely under Item 8.01 Other Events. No specific details on the nature of the event, financial metrics, transactions, or impacts are disclosed. No quantitative data, period-over-period comparisons, or scheduled events are mentioned.

17-02-2026

COMPASS Pathways plc filed an 8-K on February 17, 2026, disclosing information under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details, financial metrics, transactions, or events are mentioned in the provided filing summary. Critical content from the items and exhibits is missing.

17-02-2026

Herc Holdings Inc filed a Form 8-K on 2026-02-17 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. This is a multi-item earnings-related filing, but specific revenue, earnings, guidance, or other quantitative financial metrics are NOT_DISCLOSED. No positive or negative performance indicators, period-over-period comparisons, or material events with dollar values were detailed in the provided filing information.

17-02-2026

TE Connectivity plc filed an 8-K on February 17, 2026, reporting under Item 1.01 the entry into a material definitive agreement, under Item 1.02 the termination of a material definitive agreement, and under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No quantitative details, financial impacts, positive or negative metrics, or directional changes were disclosed.

17-02-2026

Medtronic plc filed a Form 8-K on February 17, 2026 (AccNo: 0001628280-26-008300), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with a file size of 1 MB indicating potential detailed exhibits.

17-02-2026

Waystar Holding Corp. filed an 8-K on February 17, 2026 (AccNo: 0001990354-26-000010), reporting under Item 2.02 Results of Operations and Financial Condition, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, margins, or other financial metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with no quantitative details available for analysis.

17-02-2026

Trinseo PLC filed a Form 8-K on February 17, 2026 (AccNo: 0001104659-26-015648), reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 a Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details on the agreement, transaction value, financial impacts, or performance metrics disclosed in the provided information. No quantitative data, period-over-period comparisons, or scheduled events are mentioned.

17-02-2026

DTE Energy Co filed an 8-K on February 17, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, revenue, earnings, guidance, or other quantitative data were explicitly stated in the provided filing details. This appears to be a standard earnings-related disclosure without detailed results in the excerpt.

17-02-2026

Kennedy-Wilson Holdings, Inc. filed an 8-K on February 17, 2026, disclosing under Item 1.01 entry into a material definitive agreement, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. No specific details on the nature of the agreement, events, or exhibits are provided in the filing summary. No quantitative financial metrics, period-over-period comparisons, or directional impacts are mentioned.

17-02-2026

Labcorp Holdings Inc. filed an 8-K on February 17, 2026 (AccNo: 0000920148-26-000098), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. Sector is not specified.

17-02-2026

Trinity Industries Inc filed an 8-K on 2026-02-17 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 notes financial statements and exhibits. No specific details on positions affected, individuals involved, reasons, or impacts are disclosed.

17-02-2026

WESCO INTERNATIONAL INC filed an 8-K on 2026-02-17 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). No specific details on the key position affected, individuals involved, reasons for the change, or any financial metrics are disclosed. This appears to be a routine governance disclosure with no quantified impacts mentioned.

17-02-2026

17-02-2026

Genuine Parts Co filed a Form 8-K on February 17, 2026 (AccNo: 0001193125-26-053013), reporting results of operations and financial condition under Item 2.02, other events under Item 8.01, and financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. This is a multi-item filing typical for earnings releases, with no positive or negative performance details available.

17-02-2026

Krystal Biotech, Inc. filed an 8-K on February 17, 2026, under Item 2.02 to disclose results of operations and financial condition. No specific revenue, earnings, balance sheet impacts, guidance, or quantitative metrics were provided in the filing details. This represents a standard voluntary earnings-related disclosure with no directional financial data available.

17-02-2026

Neogenomics Inc filed an 8-K on February 17, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or other quantitative financial metrics are mentioned. This is an informational earnings-related disclosure with no detailed performance data provided.

17-02-2026

Shutterstock, Inc. filed a Form 8-K on February 17, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but no specific revenue, earnings, guidance, or other quantitative metrics are provided in the filing description. No positive or negative performance indicators, period-over-period changes, or strategic details are mentioned.

17-02-2026

Axsome Therapeutics, Inc. filed a Form 8-K on February 17, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing, but specific details of the other event, transaction, financial statements, or exhibits are NOT_DISCLOSED. No quantitative metrics, positive or negative changes, or period-over-period comparisons are mentioned.

17-02-2026

Vulcan Materials Company filed an 8-K on February 17, 2026 (AccNo: 0001140361-26-005605), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing likely related to earnings or operational updates, but no specific financial metrics, positive or negative changes, guidance, or transaction details are disclosed in the provided information. All quantitative data and performance comparisons remain NOT_DISCLOSED.

17-02-2026

Knife River Corp filed a Form 8-K on February 17, 2026 (AccNo: 0001628280-26-008306), disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This multi-item filing pertains to financial results with no specific revenue, earnings, margins, or period-over-period metrics provided. Detailed quantitative data, guidance, or performance variances are NOT_DISCLOSED.

17-02-2026

Fluor Corp filed an 8-K on February 17, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no detailed quantitative data available.

17-02-2026

AIR INDUSTRIES GROUP filed a Form 8-K on February 17, 2026, reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with both mandatory (Items 1.01, 3.02) and voluntary (Item 7.01) disclosures. No quantitative details such as transaction values, share counts, financial impacts, or strategic context are disclosed.

17-02-2026

Science Applications International Corp filed an 8-K on 2026-02-17 disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected position, individual names, appointment or resignation status, reasons, or timing are provided. No quantitative financial metrics, performance comparisons, or market impacts are mentioned.

17-02-2026

USA Compression Partners, LP filed an 8-K on February 17, 2026 (AccNo: 0001522727-26-000010), reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a standard multi-item earnings-related disclosure without quantified financial impacts available.

17-02-2026

Crown PropTech Acquisitions filed an 8-K on 2026-02-17 (AccNo: 0001213900-26-016858) disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger/acquisition. Additional disclosures include Regulation FD under Item 7.01, other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific deal structure, parties, valuation, metrics, or performance details are disclosed.

17-02-2026

Coronado Global Resources Inc. filed an 8-K on February 17, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the disclosure content, financial statements, exhibits, or any metrics are provided in the filing summary. This appears to be a voluntary disclosure of material information pursuant to Regulation FD.

17-02-2026

Donnelley Financial Solutions, Inc. filed an 8-K on February 17, 2026 (AccNo: 0001193125-26-052959), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative financial metrics are disclosed in the provided filing description. This appears to be a standard earnings-related disclosure without detailed performance data available.

17-02-2026

CEVA INC filed an 8-K on February 17, 2026 (AccNo: 0001437749-26-004232), reporting Results of Operations and Financial Condition under Item 2.02 and providing Financial Statements and Exhibits under Item 9.01. This constitutes a multi-item filing for financial results disclosure. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information.

• ·Sector: not specified
• ·Source: us_sec
• ·File size: 548 KB

17-02-2026

SunocoCorp LLC filed an 8-K on February 17, 2026, under Item 2.02 for Results of Operations and Financial Condition, Item 7.01 for Regulation FD Disclosure, and Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period comparisons were disclosed in the provided filing information. This is an informational earnings-related disclosure without quantified metrics.

17-02-2026

Valmont Industries Inc filed a Form 8-K on 2026-02-17 under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are mentioned in the provided filing details. This is a standard voluntary earnings disclosure with no quantitative metrics extracted.

17-02-2026

Twist Bioscience Corp filed an 8-K on February 17, 2026, reporting unregistered sales of equity securities under Item 3.02 and other events under Item 8.01, accompanied by financial statements and exhibits under Item 9.01. No quantitative details such as transaction values, share counts, or financial impacts are disclosed. This is a multi-item informational filing with no specified positive or negative metrics.

17-02-2026

Sunoco LP filed an 8-K on February 17, 2026, disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, guidance, or other financial metrics are mentioned in the provided filing summary. This is a multi-item filing typical for earnings releases, but detailed quantitative data is NOT_DISCLOSED.

17-02-2026

Kyndryl Holdings, Inc. filed an 8-K on 2026-02-17 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on positions affected (e.g., CEO, CFO), names, reasons for changes, timing, or impacts are provided in the filing summary. No quantitative data, financial metrics, or scheduled events are mentioned.

17-02-2026

Builders FirstSource, Inc. filed an 8-K on February 17, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, period-over-period changes, or other financial metrics are disclosed in the provided filing information. No positive or negative performance details, guidance, or comparisons are available.

17-02-2026

Cyclerion Therapeutics, Inc. filed a Form 8-K on February 17, 2026, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with voluntary disclosure under Reg FD, likely including attached exhibits such as a press release, but no specific details, financial metrics, transactions, or events are disclosed in the provided filing information.

17-02-2026

APi Group Corp filed an 8-K on February 17, 2026 (AccNo: 0001628280-26-008320), specifically under Item 2.02 for Results of Operations and Financial Condition. No quantitative financial metrics, period-over-period comparisons, guidance, or other detailed results are explicitly stated in the provided filing information. Sector is not specified.

17-02-2026

M3-Brigade Acquisition V Corp. filed an 8-K on 2026-02-17 under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 for financial statements and exhibits. No specific merger/acquisition details, transaction values, parties involved, financial metrics, or period-over-period comparisons were explicitly stated in the filing information provided. Sector was not specified.

17-02-2026

Hillman Solutions Corp. filed an 8-K on February 17, 2026, under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons were detailed in the provided filing information. No positive, negative, or flat performance metrics were mentioned.

17-02-2026

SideChannel, Inc. filed an 8-K on February 17, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 5.07 (Submission of Matters to a Vote of Security Holders), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, vote outcomes, or quantitative data are disclosed in the provided filing information. This multi-item filing combines earnings-related disclosure with shareholder meeting results.

17-02-2026

Soluna Holdings, Inc. filed a Form 8-K on February 17, 2026 (AccNo: 0001493152-26-006929, Size: 272 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the Regulation FD disclosure or the nature of the exhibits are provided in the filing summary. No financial metrics, transactions, or other quantitative data are disclosed.

17-02-2026

WATSCO INC filed an 8-K on February 17, 2026 (AccNo: 0001193125-26-053048), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but provides no specific revenue, earnings, guidance, or other quantitative metrics. No positive or negative performance indicators, period-over-period changes, or segment details are mentioned.

17-02-2026

Cytokinetics Inc filed a Form 8-K on February 17, 2026, under Item 8.01 Other Events. No specific details regarding the nature of the other event, financial impacts, quantitative metrics, or scheduled events are disclosed in the provided filing information. This is a single-item voluntary disclosure with all transaction, performance, and strategic details NOT_DISCLOSED.

17-02-2026

MAINZ BIOMED N.V. filed a multi-item Form 8-K on February 17, 2026, disclosing entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), material modifications to rights of security holders (Item 3.03), departure/election of directors or officers and compensatory arrangements (Item 5.02), other events (Item 8.01), and financial statements/exhibits (Item 9.01). Specific details including transaction values, share counts, financial impacts, dollar amounts, or quantitative metrics are NOT_DISCLOSED. The combination of potential strategic agreement alongside equity issuances and rights changes suggests mixed implications, but lacks quantification for assessment.

17-02-2026

Columbia Financial, Inc. filed an 8-K on February 17, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for the change, timing, or impacts are provided in the available information. This is a required SEC disclosure for material leadership events, but lacks quantitative or qualitative context.

17-02-2026

FiscalNote Holdings, Inc. filed an 8-K on February 17, 2026 (AccNo: 0001193125-26-053083, Size: 183 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the Regulation FD disclosure content, financial statements, exhibits, transactions, metrics, or events are provided in the filing summary. This appears to be a multi-item informational filing with no disclosed quantitative data or directional impacts.

17-02-2026

Disc Medicine, Inc. filed a Form 8-K on February 17, 2026, under Item 7.01 Regulation FD Disclosure, indicating voluntary release of material nonpublic information, and Item 9.01 Financial Statements and Exhibits, likely attaching related materials such as a press release. No specific financial metrics, transactions, events, or quantitative data are disclosed in the provided filing information. Details of the disclosure content remain NOT_DISCLOSED.

17-02-2026

Energy Transfer LP filed a Form 8-K on February 17, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a standard earnings-related disclosure, but no specific financial metrics, period-over-period comparisons, or performance details (positive, negative, or flat) are provided in the filing summary. All quantitative data and operational details are NOT_DISCLOSED.

17-02-2026

Churchill Capital Corp X/Cayman filed an 8-K on February 17, 2026, disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01), marking a change in shell company status (Item 5.06). The filing also covers unregistered sales of equity securities (Item 3.02), material modifications to security holder rights (Item 3.03), changes in control (Item 5.01), director and officer changes including compensatory arrangements (Item 5.02), amendments to articles of incorporation or bylaws (Item 5.03), and amendments to the code of ethics (Item 5.05). No specific financial metrics, deal values, or performance comparisons are disclosed.

17-02-2026

News Corp filed an 8-K on February 17, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the financial statements and exhibits are disclosed. No quantitative metrics, positive or negative changes, or period-over-period comparisons are provided in the filing summary.

17-02-2026

Blue Bird Corp filed an 8-K on 2026-02-17 disclosing Item 1.01 Entry into a Material Definitive Agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, transaction value, financial impacts, or metrics are provided in the filing summary. No positive, negative, or flat performance metrics are disclosed.

17-02-2026

Danaher Corp filed a Form 8-K on February 17, 2026, disclosing Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. No specific details regarding the nature of the events, transactions, financial metrics, or exhibits are provided in the filing summary.

17-02-2026

Tianci International, Inc. filed an 8-K on February 17, 2026, disclosing Item 5.07: Submission of Matters to a Vote of Security Holders. No specific details on the matters submitted, vote outcomes, shareholder turnout, or proposals are provided in the filing summary. This is an informational filing with no financial metrics or quantitative data disclosed.

17-02-2026

CNX Resources Corp filed an 8-K on February 17, 2026 (AccNo: 0001193125-26-053115, size: 219 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing involving voluntary disclosure of material information to comply with Regulation FD, with exhibits attached. No quantitative data, financial metrics, transactions, or specific events are disclosed in the provided filing information.

17-02-2026

Cognex Corp filed an 8-K on February 17, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 7.01 covers Regulation FD Disclosure, and Item 9.01 lists financial statements and exhibits. Specific details including key position affected, appointment or resignation status, reasons for change, timing, names, and any quantitative data are NOT_DISCLOSED.

17-02-2026

XFLH Capital Corp filed a Form 8-K on February 17, 2026, reporting multiple material events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This multi-item filing signals significant corporate actions including a material agreement and potential equity dilution, but no specific transaction values, financial impacts, or further details are disclosed. No positive or negative metrics are provided, resulting in informational disclosure without directional bias.

17-02-2026

FONAR CORP filed an 8-K on February 17, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing summary. This is an informational filing on financial results with no detailed performance data available.

17-02-2026

TLGY ACQUISITION CORP filed an 8-K on 2026-02-17 under Item 8.01 Other Events related to a Merger/Acquisition event. No specific deal structure, parties involved, valuation, terms, financial metrics, or other quantitative details are disclosed in the provided filing metadata. Sector is not specified.

17-02-2026

NeuroOne Medical Technologies Corp filed an 8-K on February 17, 2026 (AccNo: 0001213900-26-016912), disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance data available.

17-02-2026

Intellinetics, Inc. filed a Form 8-K on 2026-02-17 disclosing multiple material events under Items 1.01 (Entry into a Material Definitive Agreement), 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory filing for most items, but no specific details on the agreement, obligation size, officer changes, dollar values, strategic rationale, or quantitative impacts are provided. No positive, negative, or flat metrics are mentioned.

17-02-2026

Telomir Pharmaceuticals, Inc. filed an 8-K on February 17, 2026, reporting under Item 8.01 Other Events. No specific details, financial metrics, transactions, or other quantitative data are disclosed in the provided filing information. The filing has AccNo 0001493152-26-006937 and size 207 KB.

17-02-2026

ASP Isotopes Inc. filed a Form 8-K on February 17, 2026 (AccNo: 0001477932-26-000834, size: 161 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing focused on voluntary disclosure of potentially material non-public information with attached exhibits. No financial metrics, transactions, quantitative data, or operational details are explicitly stated in the filing summary.

17-02-2026

1606 CORP. filed an 8-K on February 17, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with a document size of 156 KB (AccNo: 0001477932-26-000833). No specific financial metrics, transaction details, or performance data (positive, negative, or flat) are disclosed in the provided filing information.

17-02-2026

Playtika Holding Corp. filed an 8-K on February 17, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement. Item 9.01 references financial statements and exhibits. No specific transaction details, values, or impacts are disclosed.

17-02-2026

Strategy Inc filed a Form 8-K on February 17, 2026 (AccNo: 0001193125-26-053105), reporting under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). No specific details regarding the disclosures, financial metrics, transactions, or events are provided in the filing summary. This is a multi-item filing with no quantitative data or directional impacts disclosed.

17-02-2026

FRANKLIN ELECTRIC CO INC filed an 8-K on 2026-02-17 under Item 2.02 disclosing Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, margins, or period-over-period comparisons are mentioned. This appears to be a standard voluntary earnings-related disclosure with attached exhibits.

• ·Accession Number: 0000038725-26-000002
• ·File Size: 451 KB

17-02-2026

Graham Corp filed an 8-K on February 17, 2026 (AccNo: 0001193125-26-053140), reporting under Item 5.02 on departure of directors or certain officers, election/appointment of directors/officers, and compensatory arrangements; Item 7.01 on Regulation FD disclosure; and Item 9.01 on financial statements and exhibits. Specific details including officer names, positions, reasons for change, timing, or any financial metrics are NOT_DISCLOSED. No quantitative data, performance comparisons, or scheduled events are mentioned.

17-02-2026

Pangaea Logistics Solutions Ltd. filed an 8-K on February 17, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific event details, financial metrics, transactions, or comparisons are provided in the filing summary. No positive or negative metrics are mentioned.

17-02-2026

Cogent Biosciences, Inc. filed a Form 8-K on February 17, 2026 (AccNo: 0001193125-26-053131), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were mentioned. This is a standard financial results announcement without quantified metrics provided.

17-02-2026

Invech Holdings, Inc. filed a Form 8-K on February 17, 2026, disclosing multiple material events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.01 (Changes in Control of Registrant), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), and 9.01 (Financial Statements and Exhibits). No specific details on transaction values, parties involved, financial impacts, or changes are provided in the filing summary. This multi-item filing indicates a potentially transformative corporate event such as a merger or acquisition leading to control changes, but lacks quantitative data for assessment.

17-02-2026

Turn Therapeutics Inc. filed a Form 8-K on February 17, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details, financial metrics, transactions, or quantitative data are explicitly stated in the provided filing summary. The filing size is 212 KB with Accession Number 0001213900-26-016916.

17-02-2026

Cingulate Inc. filed an 8-K on 2026-02-17 disclosing events under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), alongside Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). Specific details including affected positions, names, appointment or resignation status, reasons, and any financial impacts are NOT_DISCLOSED. No quantitative metrics, period-over-period comparisons, or scheduled events were mentioned.

17-02-2026

Gemini Space Station, Inc. filed an 8-K on 2026-02-17 disclosing results of operations and financial condition under Item 2.02 and an officer or director change, including potential compensatory arrangements, under Item 5.02. No specific details such as the key position affected, appointment or resignation status, reasons for the change, board impacts, financial metrics, or quantitative data are provided. The filing is informational with no disclosed positive or negative performance indicators.

17-02-2026

Conagra Brands Inc. filed an 8-K on February 17, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, guidance, or scheduled events are detailed in the filing summary provided. This is a multi-item filing likely involving voluntary disclosure of material non-public information with attached exhibits.

17-02-2026

LGI Homes, Inc. filed an 8-K on February 17, 2026 (AccNo: 0001580670-26-000007, Size: 493 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific revenue, earnings, guidance, metrics, period-over-period changes, or other quantitative details are mentioned in the provided filing information.

17-02-2026

Cousins Properties Inc filed an 8-K on February 17, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events or the nature of the attached financial statements and exhibits are disclosed in the provided filing summary. This appears to be an informational disclosure without quantified financial impacts.

17-02-2026

CNS Pharmaceuticals, Inc. filed an 8-K on February 17, 2026 (AccNo: 0001683168-26-001066), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the key position affected (e.g., CEO, CFO), whether it is an appointment or resignation, reasons for the change, timing, or any compensatory arrangements are disclosed. No quantitative metrics, financial data, or performance comparisons are provided.

17-02-2026

MaxLinear, Inc. filed an 8-K on 2026-02-17 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 references financial statements and exhibits. No specific details on the affected officer, position, appointment or resignation, reasons, or quantitative impacts are disclosed.

• ·Event date: February 17, 2026
• ·Filing accession number: 0001288469-26-000017
• ·File size: 210 KB

17-02-2026

Glimpse Group, Inc. filed an 8-K on February 17, 2026 (AccNo: 0001493152-26-006950), reporting under Item 2.02 Results of Operations and Financial Condition, with Item 9.01 Financial Statements and Exhibits. This is a multi-item filing disclosing financial results, but no specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance are provided in the filing description. Sector is not specified.

17-02-2026

ITRON, INC. filed a Form 8-K on February 17, 2026 (AccNo: 0001171843-26-000850, Size: 637 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics were disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed financial data available.

• ·File size: 637 KB
• ·Sector: NOT_DISCLOSED

17-02-2026

Moleculin Biotech, Inc. filed an 8-K on February 17, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transactions, events, or quantitative data are disclosed in the filing summary provided. This appears to be a multi-item informational filing with attached exhibits.

17-02-2026

Investors Title Co filed an 8-K on February 17, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, period-over-period comparisons, guidance, or other quantitative financial metrics were explicitly stated in the provided filing details. This appears to be a standard voluntary earnings-related disclosure without detailed performance data.

17-02-2026

D. Boral Acquisition I Corp. filed an 8-K on 2026-02-17 announcing entry into a material definitive agreement under Item 1.01, unregistered sales of equity securities under Item 3.02, departure/election/appointment of directors/officers and compensatory arrangements under Item 5.02, amendments to articles of incorporation or bylaws or change in fiscal year under Item 5.03, other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific details on deal parties, structure, valuation, synergies, or financial metrics are disclosed. No positive or negative performance metrics are provided in the filing summary.

17-02-2026

Cooper-Standard Holdings Inc. filed an 8-K on February 17, 2026, reporting Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. No specific details regarding the nature of the other events or the contents of the exhibits are disclosed in the filing summary. This is an informational filing with no quantified financial metrics, positive or negative changes reported.

17-02-2026

Bowman Consulting Group Ltd. filed an 8-K on 2026-02-17 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officer, position (e.g., CEO, CFO), nature of change (appointment or resignation), reasons, timing, or any quantitative financial metrics are disclosed. This appears to be a routine governance disclosure without additional performance data.

17-02-2026

Signing Day Sports, Inc. filed an 8-K on February 17, 2026 (AccNo: 0001213900-26-016927, size: 264 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing focused on voluntary disclosure of potentially material information with attached exhibits. No specific financial metrics, transactions, or quantitative data are disclosed.

17-02-2026

Outlook Therapeutics, Inc. filed an 8-K on 2026-02-17 reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits provided under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics are explicitly stated in the filing summary provided.

17-02-2026

Nukkleus Inc. filed an 8-K on 2026-02-17 announcing the completion of an acquisition or disposition of assets under Item 2.01, with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on deal parties, structure, valuation, synergies, or financial impacts were disclosed. Sector not specified, limiting assessment of strategic implications.

17-02-2026

CPI Card Group Inc. filed an 8-K on 2026-02-17 (AccNo: 0001104659-26-015886, Size: 140 KB) under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details such as names, titles, reasons for change, timing, or financial implications are explicitly stated in the provided filing summary. No quantitative metrics, performance comparisons, or other events are mentioned.

• ·Event date: 2026-02-17
• ·Source: us_sec
• ·Sector: NOT_DISCLOSED

17-02-2026

HireQuest, Inc. filed a Form 8-K on February 17, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This multi-item filing ensures broad dissemination of material non-public information and includes attached exhibits. No specific financial metrics, transaction details, positive or negative changes, or other quantitative data are disclosed in the provided filing information.

17-02-2026

Howmet Aerospace Inc. filed a Form 8-K on February 17, 2026 (AccNo: 0001104659-26-015914), reporting under Item 8.01 Other Events. No specific details regarding the nature of the other event, financial metrics, transactions, or scheduled events are disclosed in the provided filing information. Sector is not specified.

17-02-2026

Stabilis Solutions, Inc. filed a Form 8-K on February 17, 2026, under Item 2.02 for results of operations and financial condition, Item 7.01 for Regulation FD disclosure, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed. This is a multi-item filing announcing financial results with no detailed performance data provided.

17-02-2026

OMNIQ Corp. filed an 8-K on February 17, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure, financial statements, exhibits, transactions, metrics, or events are disclosed in the provided filing information. This is a multi-item filing likely involving voluntary disclosure with supporting attachments.

17-02-2026

Masimo Corp filed a Form 8-K on February 17, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details provided on the agreement's nature, parties, terms, financial impacts, or any quantitative metrics such as transaction value, revenue effects, or guidance changes. No positive or negative metrics are disclosed, resulting in purely informational disclosure.

17-02-2026

VisionWave Holdings, Inc. filed a Form 8-K on 2026-02-17 disclosing under Item 1.01 entry into a material definitive agreement. Item 9.01 includes financial statements and exhibits. No details on the agreement terms, transaction value, financial impacts, strategic rationale, or any quantitative metrics are disclosed.

17-02-2026

BITMINE IMMERSION TECHNOLOGIES, INC. filed an 8-K on February 17, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing voluntarily disclosing material nonpublic information to comply with Regulation FD, with exhibits attached. No specific transaction details, financial metrics, positive or negative changes, or quantitative data are mentioned in the filing summary.

17-02-2026

Royal Caribbean Cruises Ltd filed a Form 8-K on February 17, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officer, reason for change, timing, or any quantitative metrics are provided.